Overview

Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19

Status:
NOT_YET_RECRUITING

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.

Phase:

PHASE2

Details

Lead Sponsor:

Traws Pharma, Inc.

Treatments:

nirmatrelvir and ritonavir drug combination